Translate Bio, Inc.
Translate Bio, Inc. (TBIO): 3 pipeline candidates · ~35 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
35.2 months
D/E 1.19 · 6% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Translate Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2K
Cash
$254.3M
Quarterly Burn
$56.6M
Runway
35.2 mo
Revenue
$72.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| infectious disease vaccines | Preclinical |
| mrt5005 | Phase 2 |
| mrt5500 | Preclinical |
Frequently asked questions
How many drug candidates are in Translate Bio, Inc.'s pipeline?
Translate Bio, Inc. (TBIO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Translate Bio, Inc.'s lead drug candidate?
Translate Bio, Inc.'s most advanced tracked candidate is infectious disease vaccines (Preclinical) for infectious disease.
What is Translate Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Translate Bio, Inc. has approximately 35.2 months of cash runway.
What is Translate Bio, Inc.'s market capitalization?
Translate Bio, Inc.'s market capitalization is approximately $2K.
Who is the CEO of Translate Bio, Inc.?
Mr. Eric Esser is the chief executive officer of Translate Bio, Inc. (TBIO).
Get the full picture on Translate Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.